治疗诊断学全球市场

预计到 2029年终，全球治疗诊断学市场规模将达到 127 亿美元，预测期内复合年增长率为 24.0%，从 2023 年的 37 亿美元到 2024 年的 43 亿美元。

治疗诊断学设备产业预计将从 2024 年的 22 亿美元增至 2029 年底的36 亿美元，复合年增长率为 9.7%。此外，治疗诊断学领域预计将从 2024 年的 21 亿美元成长到 2029 年底的91 亿美元，复合年增长率为 34.5%。

本报告调查了全球治疗诊断学市场，并提供了市场概况、市场影响因素和市场机会分析、新兴技术和技术发展趋势、市场规模趋势和预测、各个细分市场和地区的详细分析，总结了竞争格局、概况主要企业等

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场概况

第二章 市场概况

• 概述
• PESTLE分析
• 波特五力分析
• 研究开发和监管核准
• 药物研发流程
• NDA资料审查
• 治疗诊断学临床试验
• 临床试验中的放射治疗程序

第三章市场动态

• 市场动态
• 市场驱动因素
• 治疗诊断学作为传统治疗方法的替代方案
• 在药物发现中越来越多地使用治疗诊断学
• 由于慢性病的传播，对个人化治疗的需求增加
• 新的放射治疗推动治疗诊断学市场
• 慢性发炎疾病增加
• 新兴国家的癌症流行
• 市场限制因素
• 治疗诊断学费用高成本
• 市场挑战
• 奈米治疗学与生物技术之间的相互作用
• 放射治疗的挑战
• 放射治疗失败
• 市场机会
• 心血管疾病治疗诊断学

第四章新兴科技与发展

• 人工智慧在治疗诊断学的应用
• 使用创新材料的药物输送
• 硼中子捕获疗法（BNCT）
• 发光体聚集诱导发射 (AIE)
• 类风湿性关节炎(RA) 的治疗诊断学

第五章市场区隔分析

• 细分细分
• 市场分析：依产品类型
• 治疗诊断学设备
• 治疗诊断学药物
• 诊断剂
• 治疗药物
• 市场分析：依应用分类
• 癌症的病因学
• 癌症诊断
• 癌症治疗药物
• 摄护腺癌
• 神经内分泌肿瘤
• 甲状腺癌
• 神经母细胞瘤
• 其他疾病
• 地域分布
• 市场分析：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他领域

第六章 竞争讯息

• 战略分析
• 临床试验分析

第七章治疗诊断学市场的永续性：ESG 视角

• ESG：简介
• 治疗诊断学市场的关键 ESG 问题
• 员工安全
• 放射性废弃物处置
• 奈米污染
• ESG 在治疗诊断学市场的现状
• ESG绩效分析
• BCC 的结论

第8章附录

• 调查方法
• 来源
• 缩写词
• 公司简介
• BAYER AG
• CURIUM PHARMA
• GE HEALTHCARE
• LANTHEUS
• NOVARTIS AG
• SIEMENS HEALTHINEERS AG
• TELIX PHARMACEUTICALS LTD.
• 其他公司

The global market for theranostics was valued at $3.7 billion in 2023. The market is expected to grow from $4.3 billion in 2024 to $12.7 billion by the end of 2029, at a compound annual growth rate, or CAGR, of 24.0% from 2024 to 2029.

The global market for theranostics equipment is expected to grow from $2.2 billion in 2024 to $3.6 billion by the end of 2029, at a CAGR of 9.7% from 2024 to 2029.

The global market for theranostics agents is expected to grow from $2.1 billion in 2024 to $9.1 billion by the end of 2029, at a CAGR of 34.5% from 2024 to 2029.

Report Scope:

This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.

Report Includes:

45 data tables and 37 additional tables

• An overview of the global markets for theranostics
• Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
• Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
• Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
• Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
• Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
• A discussion of ESG challenges and ESG practices in the industry
• Analysis of the key companies' market shares, proprietary technologies and strategic alliances
• Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• PESTLE Analysis
• Political
• Economic
• Social
• Technological
• Legal
• Environmental
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential of New Entrants
• Competition in the Industry
• Threat of Substitutes
• R&D and Regulatory Approval
• The Drug Development Process
• Drug Discovery
• Preclinical Development
• Clinical Trials
• The New Drug Application Review
• NDA Data Review
• Clinical Trials for Theranostics
• Steps Followed for Radiotherapeutics in Clinical Trials

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Theranostics Replacing Conventional Treatment
• Increased Application of Theranostics in Drug Discovery
• Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
• New Radiotheranostics Driving the Theranostics Market
• Rise in Chronic Inflammatory Diseases
• Cancer Epidemics in Developing Countries
• Market Restraints
• High Cost of Theranostics
• Market Challenges
• Nanotheranostics-Bio Interactions
• Challenges of Radiotheranostics
• Failure of Radiotherapeutics
• Market Opportunities
• Theranostics in Cardiovascular Diseases

Chapter 4 Emerging Technologies and Developments

• Artificial Intelligence in Theranostics
• Drug Delivery Using Innovative Material
• Boron Neutron Capture Therapy (BNCT)
• Luminogen Aggregation-Induced Emission (AIE)
• Theranostics in Rheumatoid Arthritis (RA)

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Product Type
• Theranostics Equipment
• Theranostics Agents
• Diagnostics Theranostics Agents
• Therapeutics Theranostics Agents
• Market Analysis, by Application
• Etiology of Cancer
• Cancer Diagnosis
• Cancer Therapeutics
• Prostate Cancer
• Neuroendocrine Tumors
• Thyroid Cancer
• Neuroblastoma
• Other Diseases
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Strategic Analysis
• Clinical Trials Analysis

Chapter 7 Sustainability in Theranostics Market: An ESG Perspective

• Introduction to ESG
• Key ESG Issues in the Theranostics Market
• Safety of Personnel
• Disposal of Radioactive Waste
• Nanopollution
• Current Status of ESG in the Theranostics Market
• ESG Performance Analysis
• Concluding Remark from BCC Research

Chapter 8 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• BAYER AG
• CURIUM PHARMA
• GE HEALTHCARE
• LANTHEUS
• NOVARTIS AG
• SIEMENS HEALTHINEERS AG
• TELIX PHARMACEUTICALS LTD.
• Other Companies

List of Tables

• Summary Table : Global Market for Theranostics, by Product Type, Through 2029
• Table 1 : Approved Radiopharmaceuticals for Radiotheranostics, 2024
• Table 2 : Worldwide Regulatory Authorities, 2024
• Table 3 : Dosimetry Pre-therapy and Post-therapy
• Table 4 : Global Market for Theranostics, by Product Type, Through 2029
• Table 5 : Global Market for Theranostics Equipment, by Type, Through 2029
• Table 6 : Global Market for Theranostics Equipment, by Region, Through 2029
• Table 7 : Global Market for PET Theranostics Equipment, by Region, Through 2029
• Table 8 : Global Market for SPECT Theranostics Equipment, by Region, Through 2029
• Table 9 : Global Market for MRI Theranostics Equipment, by Region, Through 2029
• Table 10 : Global Market for Other Theranostics Equipment, by Region, Through 2029
• Table 11 : Global Market for Theranostics Agents, by Type, Through 2029
• Table 12 : Global Market for Theranostics Agents, by Region, Through 2029
• Table 13 : Select Theranostics Pair
• Table 14 : Properties of Commonly Used Radionuclides in Theranostics
• Table 15 : Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
• Table 16 : Difference Between Alpha Particles and Beta Particles
• Table 17 : Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
• Table 18 : Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
• Table 19 : Advantages and Disadvantages of Various Cancer Treatments
• Table 20 : Global Market for Theranostics Applications, by Type, Through 2029
• Table 21 : Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
• Table 22 : Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
• Table 23 : Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
• Table 24 : Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
• Table 25 : Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
• Table 26 : Estimated Number of Cancer Deaths Per Region, 2022 and 2045
• Table 27 : North American Market for Theranostics, by Product Type, Through 2029
• Table 28 : North American Market for Theranostics Equipment, by Type, Through 2029
• Table 29 : North American Market for Theranostics Agents, by Type, Through 2029
• Table 30 : North American Market for Theranostics Applications, by Type, Through 2029
• Table 31 : North American Market for Theranostics, by Country, Through 2029
• Table 32 : Theranostics Centers Needed in the U.S.
• Table 33 : European Market for Theranostics, by Product Type, Through 2029
• Table 34 : European Market for Theranostics Equipment, by Type, Through 2029
• Table 35 : European Market for Theranostics Agents, by Type, Through 2029
• Table 36 : European Market for Theranostics Applications, by Type, Through 2029
• Table 37 : European Market for Theranostics, by Country, Through 2029
• Table 38 : Asia-Pacific Market for Theranostics, by Product Type, Through 2029
• Table 39 : Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
• Table 40 : Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
• Table 41 : Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
• Table 42 : Asia-Pacific Market for Theranostics, by Country, Through 2029
• Table 43 : Rest of the World Market for Theranostics, by Product Type, Through 2029
• Table 44 : Rest of the World Market for Theranostics Equipment, by Type, Through 2029
• Table 45 : Rest of the World Market for Theranostics Agents, by Type, Through 2029
• Table 46 : Rest of the World Market for Theranostics Applications, by Type, Through 2029
• Table 47 : Market Ranking, Theranostics Agents
• Table 48 : Strategic Analysis: Theranostics Market, 2021-2024
• Table 49 : Targeted Radioligands Therapy in Clinical Trials, 2024
• Table 50 : The Three Pillars of ESG
• Table 51 : ESG Ranking of Leading Theranostics Players
• Table 52 : ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
• Table 53 : Report Information Sources
• Table 54 : Major Acronyms Used in the Global Theranostics Market
• Table 55 : Bayer AG: Company Snapshot
• Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 57 : Bayer AG: Product Portfolio
• Table 58 : Bayer AG: News/Key Developments, 2021-2023
• Table 59 : Curium Pharma: Company Snapshot
• Table 60 : Curium Pharma: Product Portfolio
• Table 61 : GE Healthcare: Company Snapshot
• Table 62 : GE Healthcare: Financial Performance, FY 2022 and 2023
• Table 63 : GE Healthcare: Product Portfolio
• Table 64 : GE Healthcare: News/Key Developments, 2023-2024
• Table 65 : Lantheus: Company Snapshot
• Table 66 : Lantheus: Financial Performance, FY 2022 and 2023
• Table 67 : Lantheus: Product Portfolio
• Table 68 : Lantheus: News/Key Developments, 2023-2024
• Table 69 : Novartis AG: Company Snapshot
• Table 70 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 71 : Novartis AG: Product Portfolio
• Table 72 : Novartis AG: News/Key Developments, 2022
• Table 73 : Siemens Healthineers AG: Company Snapshot
• Table 74 : Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
• Table 75 : Siemens Healthineers AG: Product Portfolio
• Table 76 : Siemens Healthineers AG: News/Key Developments, 2022
• Table 77 : Telix Pharmaceutical Ltd.: Company Snapshot
• Table 78 : Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
• Table 79 : Telix Pharmaceutical Ltd.: Product Portfolio
• Table 80 : Telix Pharmaceutical Ltd.: News/Key Developments, 2022-2024
• Table 81 : Upcoming Startups in The Field of Theranostics

List of Figures

• Summary Figure : Global Market for Theranostics, by Product Type, 2021-2029
• Figure 1 : Theranostics Workflow
• Figure 2 : Components of the Drug Approval Process
• Figure 3 : Preclinical and Clinical Trials Phases
• Figure 4 : Clinical Trials Radionuclide Pictorial Representative, 2024
• Figure 5 : Market Dynamics of Theranostics
• Figure 6 : Disadvantages of Chemotherapy Treatment
• Figure 7 : Drug Development Cost, 2002 and 2022
• Figure 8 : Global Market Shares of Theranostics, by Product Type, 2023
• Figure 9 : Global Market Shares of Theranostics, by Product Type, 2029
• Figure 10 : Global Market Shares of Theranostics Equipment, by Type, 2023
• Figure 11 : Global Market Shares of Theranostics Agents, by Type, 2023
• Figure 12 : Schematic Representation of Radionuclide Therapy
• Figure 13 : Schematic Representation of Radionuclide Therapy
• Figure 14 : Etiology of Cancer
• Figure 15 : Cancer Diagnostics Methods
• Figure 16 : Types of Imaging
• Figure 17 : Asia-Pacific Cancer Incidence, 2008 and 2030
• Figure 18 : Global Market Shares of Theranostics Instruments, by Installation Base, 2024
• Figure 19 : Share of Clinical Trials, by Recruiting Status, 2024
• Figure 20 : Share of Clinical Trials, by Type of Indication, 2024
• Figure 21 : Share of Clinical Trials, by Phase, 2024
• Figure 22 : Share of Clinical Trials, by Type of Funder, 2024
• Figure 23 : Share of Clinical Trials, by Gender, 2024
• Figure 24 : The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
• Figure 25 : ESG Concerns in the Theranostics Market
• Figure 26 : Bayer AG: Revenue Share, by Business Unit, FY 2023
• Figure 27 : Bayer AG: Revenue Share, by Country/Region, FY 2023
• Figure 28 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
• Figure 29 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
• Figure 30 : Lantheus: Revenue Share, by Business Unit, FY 2023
• Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 33 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
• Figure 34 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
• Figure 35 : Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023